



		hopra & Microbiology) onsultant Pathologist	Dr. Yugan MD CEO & Consultant	(Pathology)
AME	: Mrs. RENU SHARMA			
GE/ GENDER	: 51 YRS/FEMALE	PAT	TIENT ID	: 1655032
OLLECTED BY	:	REG	. NO./LAB NO.	: 012410280009
EFERRED BY	:	REG	SISTRATION DATE	: 28/Oct/2024 08:14 AM
ARCODE NO.	:01519672	COI	LECTION DATE	: 28/Oct/2024 08:40AM
LIENT CODE.	: KOS DIAGNOSTIC LAB	REF	ORTING DATE	: 28/Oct/2024 09:05AM
LIENT ADDRESS	: 6349/1, NICHOLSON ROAI	D, AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
issues back to the lur low hemoglobin leve NEMIA (DECRESED H) Loss of blood (trau	igs. el is referred to as ANEMIA or AEMOGLOBIN): matic injury, surgery, bleeding	low red blood count.		odys tissues and returns carbon dioxide from the
) Bone marrow probl) Suppression by red) Kidney failure) Abnormal hemoglo	cy (iron, vitamin B12, folate) ems (replacement of bone ma blood cell synthesis by chemo bin structure (sickle cell anen E ASED HAEMOGLOBIN): titudes (Physiological)	otherapy drugs		





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



Page 1 of 6



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



BIQ.	ACCREDITED (A Unit of KO	DS Healthcare)	EXCELLENCE IN HEALTHCARE	
	Dr. Vinay Cho MD (Pathology & Chairman & Cons	Microbiology)	Dr. Yugan MD CEO & Consultant	(Pathology)
NAME AGE/ GENDER COLLECTED BY REFERRED BY BARCODE NO. CLIENT CODE. CLIENT ADDRESS	: Mrs. RENU SHARMA : 51 YRS/FEMALE : : : 01519672 : KOS DIAGNOSTIC LAB : 6349/1, NICHOLSON ROAD, A	REG. REG COLI REP(IENT ID NO./LAB NO. ISTRATION DATE LECTION DATE DRTING DATE	: 1655032 : 012410280009 : 28/Oct/2024 08:14 AM : 28/Oct/2024 08:40AM : 28/Oct/2024 04:43PM
Test Name		Value	Unit	Biological Reference interval
LDL CHOLESTERO	LOW DENSITY LI L (DIRECT): SERUM	AL CHEMISTRY IPOPROTEIN (LD 116.9		
	DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROE		PATHOLOGIST	

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







	Dr. Vinay Ch MD (Pathology & Chairman & Cor			(Pathology)
NAME	: Mrs. RENU SHARMA			
AGE/ GENDER	: 51 YRS/FEMALE		PATIENT ID	: 1655032
COLLECTED BY	:		REG. NO./LAB NO.	: 012410280009
REFERRED BY	:		REGISTRATION DATE	: 28/Oct/2024 08:14 AM
BARCODE NO.	: 01519672		COLLECTION DATE	: 28/Oct/2024 08:40AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 30/Oct/2024 10:51AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
		ENDOC	RINOLOGY	
	TS	H RECEPTOR	ANTIBODY (TRAB)	
IMMUNOASSAY)	NTIBODY vescence microparticle	16.22 ^H	IU/L	Normal : <=2.58
INTERPRETATION:	PTOR ANTIBODY LEVEL (IU/L)		REMARKS	
	1.00 (97.5 th percentile)		Upper limit in healthy	individual
	1.58 (97.5 th percentile)	Thyro	oid Disease without diagnos	
	% Senstivity & 99 % Specificity)		Suggestive of Graves	s disease

NOTE:

1. In patients receiving high dose Biotin therapy (>5 mg/day), the specimen should not be collected for at least 8 hours after the last biotin administration.

2. Sodium heparin therapy interferes with this assay hence sampling from these patients is not recommended.

3. Rarely high titers of antibodies to Streptavidin and Ruthenium may also interfere with the assay.

COMMENTS

TSH Receptor stimulating antibodies are most closely associated with disease pathogenesis in all forms of Autoimmune thyrotoxicosis (Graves disease), Hashitoxicosis & Neonatal Thyrotoxicosis. These antibodies may be detected before Autoimmune thyrotoxicosis becomes biochemically or clinically manifest. Since treatments for Graves disease are not aimed at underlying disease process but deal with ablation of thyroid tissue, these antibodies may persist even after apparent clinical cure. This is specially relevant in pregnant women with Graves disease treated with thyroid ablative therapy who continue to produce thyroid receptor antibodies which can cross the placental barrier and cause Neonatal thyrotoxicosis.

USES:

1. Differential diagnosis of etiology of Thyrotoxicosis in patients with ambiguous clinical findings, non diagnostic thyroid radio-isotope scans & in pregnant or breast feeding females where thyroid radio-isotope scans are contraindicated

2. Diagnosis of clinically suspected Graves disease (Extra thyroidal manifestation of Graves disease, Endocrine Exophthalmus, Pretibial Myxedama, Thyroid acropachy) in patients with normal thyroid function tests

3. Determining risk of Neonatal thyrotoxicosis in a pregnant female with active or past history of Graves disease

4. Differential diagnosis of Gestational Thyrotoxicosis versus First trimester manifestation or recurrence of Graves disease

5. Assessing the risk of Graves disease relapse after antithyroid therapy





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com







		hopra & Microbiology) onsultant Pathologist	Dr. Yugan MD CEO & Consultant	(Pathology)	
NAME	: Mrs. RENU SHARMA				
AGE/ GENDER	: 51 YRS/FEMALE	PATI	ENT ID	: 1655032	
COLLECTED BY	:	REG.	NO./LAB NO.	: 012410280009	
REFERRED BY	:	REGI	STRATION DATE	: 28/Oct/2024 08:14 AM	
BARCODE NO.	:01519672	COLL	ECTION DATE	: 28/Oct/2024 08:40AM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB		RTING DATE	: 28/Oct/2024 12:36PM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAI				
Test Name		Value	Unit	Biological Referen	nce interva
THYROID STIMULA by CMIA (CHEMILUMIN Srd GENERATION, ULT INTERPRETATION: TSH levels are subject to of day has influence on the l	IESCENT MICROPARTICLE IMMUNC ATING HORMONE (TSH): SEI IESCENT MICROPARTICLE IMMUNC RASENSITIVE circadian variation, reaching peak levi measured serum TSH concentrations.	RUM 0.03^L ASSAY) els between 2-4 a.m and at a m TSH stimulates the production	and secretion of the m	4.87 - 12.60 0.35 - 5.50 m. The variation is of the order of 50%. letabolically active hormones, thyroxir er underproduction (hypothyroidism) of	ne (T4)and
overproduction(hyperthy CLINICAL CONDITION	vroidism) of T4 and/or T3.	T4		TSH	
Primary Hypothyroidisi			uced	ncreased (Significantly)	
Subclinical Hypothyroid			or Low Normal	High	
	sm: Increase	d Incr	eased F	Reduced (at times undetectable)	
Primary Hyperthyroidis					

1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG), and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests.

2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs (e.g.: phenytoin , salicylates).

3. Serum T4 levels in neonates and infants are higher than values in the normal adult , due to the increased concentration of TBG in neonate serum.

4. TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy.

TRIIODOTHYRONINE (T3)		THYROX	THYROXINE (T4)		THYROID STIMULATING HORMONE (TSH)		
Age	Refferance Range (ng/mL)	Age	Refferance Range (µg/dL)	Age	Reference Range (µIU/mL)		
0 - 7 Days	0.20 - 2.65	0 - 7 Days	5.90 - 18.58	0 - 7 Days	2.43 - 24.3		
7 Days - 3 Months	0.36 - 2.59	7 Days - 3 Months	6.39 - 17.66	7 Days - 3 Months	0.58 - 11.00		
3 - 6 Months	0.51 - 2.52	3 - 6 Months	6.75 - 17.04	3 Days – 6 Months	0.70 - 8.40		
6 - 12 Months	0.74 - 2.40	6 - 12 Months	7.10 - 16.16	6 – 12 Months	0.70 - 7.00		
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50		





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT





	Dr. Vinay Chopra MD (Pathology & Microt Chairman & Consultant I	G, /	(Pathology)	
NAME	: Mrs. RENU SHARMA			
AGE/ GENDER	: 51 YRS/FEMALE	PATIENT ID	: 1655032	
COLLECTED BY	:	REG. NO./LAB NO.	: 012410280009	
REFERRED BY	:	REGISTRATION DATE	: 28/Oct/2024 08:14 AM	
BARCODE NO.	: 01519672	COLLECTION DATE	: 28/Oct/2024 08:40AM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPORTING DATE	: 28/Oct/2024 12:36PM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBAL	A CANTT		

est Name	Value	Unit		Biological Reference interval
11- 19 Years 0.35 - 1.93 11 - 19 Years	4.87-13.20	11 – 19 Years	0.50 - 5.50	
> 20 years (Adults) 0.35 - 1.93 > 20 Years (Adul	ts) 4.87 - 12.60	> 20 Years (Adults)	0.35-5.50	
RECOMMENDATIONS OF T	SH LEVELS DURING PREC	GNANCY (µIU/mL)		
1st Trimester		0.10 - 2.50		
2nd Trimester		0.20 - 3.00		
3rd Trimester		0.30 - 4.10		

INCREASED TSH LEVELS:

1. Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.

2. Hypothyroid patients receiving insufficient thyroid replacement therapy.

3. Hashimotos thyroiditis

4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.

5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

DECREASED TSH LEVELS:

1.Toxic multi-nodular goiter & Thyroiditis.

2. Over replacement of thyroid hormone in treatment of hypothyroidism.

3. Autonomously functioning Thyroid adenoma

4. Secondary pituitary or hypothalamic hypothyroidism

5.Acute psychiatric illness

6.Severe dehydration.

7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.

8. Pregnancy: 1st and 2nd Trimester



am

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com





TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



KOS Diagnostic Lab (A Unit of KOS Healthcare)

		0 M ¹ h ¹ - l h	Dr. Yugam	
	Chairman & Co	& Microbiology) onsultant Pathologist	MD CEO & Consultant	(Pathology) Pathologist
IAME	: Mrs. RENU SHARMA			
GE/ GENDER	: 51 YRS/FEMALE	PATI	ENT ID	: 1655032
OLLECTED BY	:	REG.	NO./LAB NO.	: 012410280009
REFERRED BY	:	REGIS	STRATION DATE	: 28/Oct/2024 08:14 AM
ARCODE NO.	: 01519672	COLL	ECTION DATE	: 28/Oct/2024 08:40AM
LIENT CODE.	: KOS DIAGNOSTIC LAB	REPO	RTING DATE	: 28/Oct/2024 10:46AM
LIENT ADDRESS	: 6349/1, NICHOLSON ROAD), AMBALA CANTT		
Fest Name		Value	Unit	Biological Reference interval
	IM	MUNOPATHOLO	GY/SEROLOGY	Y
	ANTI THYR	OID PEROXIDASE (TPO/AMA) ANT	TIBODIES
	NTIBODIES: SERUM IESCENCE IMMUNOASSAY)	> 1000.0 ^H	IU/mL	0.00 - 10.0 DIABETES (II): < 25.0
. Graves disease . Post-partum thyro . Primary hypothyro IOTE:	oidism due to Hashimoto thyroi			
. The highest TPO a ntibodies is about 9 . These auto-antibo . In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	In this disease, the prevalence of TPO an increased risk of developing overt
The highest TPO a ntibodies is about 9 These auto-antibo In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr	sease. aves disease. es is associated with	
. The highest TPO a ntibodies is about 9 . These auto-antibo . In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
. The highest TPO a ntibodies is about 9 . These auto-antibo . In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
I. The highest TPO a antibodies is about 9 2. These auto-antibo 3. In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
I. The highest TPO a antibodies is about 9 2. These auto-antibo 3. In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
 The highest TPO a antibodies is about 9 These auto-antibo In patients with si 	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
 The highest TPO a antibodies is about 9 These auto-antibo In patients with si 	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
1. The highest TPO a antibodies is about 9 2. These auto-antibo 3. In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
1. The highest TPO a antibodies is about 9 2. These auto-antibo 3. In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
1. The highest TPO a antibodies is about 9 2. These auto-antibo 3. In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
1. The highest TPO a antibodies is about 9 2. These auto-antibo	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with	
1. The highest TPO a antibodies is about 9 2. These auto-antibo 3. In patients with su	90% of cases, confirming the au odies also frequently occur (60%	toimmune origin of the di -80%) in the course of Gr presence of TPO antibodie	sease. aves disease. es is associated with ***	

